CAS: 2088939-99-3

LYN-1604 is a small-molecule drug that is a potential drug target for cancer therapy. It has been shown to inhibit autophagy and induce apoptosis in cancer cells, including breast cancer tissues. LYN-1604 binds to the rapamycin complex in the cytoplasm and inhibits mTORC1 activity, which results in reduced protein synthesis and induction of autophagy. This compound also has an antitumor effect on corneal epithelium and cancer tissues.

LYN-1604

LYN-1604 is a novel activator of ULK1, inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.